Drug Profile
ISA 201
Alternative Names: Amplivant-HPV16SLP conjugate; Hespecta; HPV E-Six Peptide Conjugated To AMPLIVANT®; HPV16 E6 Peptide Conjugated To AMPLIVANT®; HPV16 peptides AMPLIVANT® vaccine; ISA201; SLP AMPLIVANT® head and neck cancer vaccineLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator ISA Pharmaceuticals
- Developer ISA Pharmaceuticals; Leiden University Medical Center
- Class Cancer vaccines; Conjugate vaccines; Peptide vaccines; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Human-papillomavirus-infections in Netherlands (SC)
- 12 Apr 2023 Phase-II clinical trials in Head and neck cancer in Netherlands (SC) (ISA Pharmaceuticals pipeline, April 2023)
- 04 Jun 2021 Phase-I development is ongoing in the Netherlands